37 results about "Multiple administration" patented technology

The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble CD1d complexes, in particular non-specific soluble CD1d complexes. Soluble CD1d complexes comprise a soluble CD1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the CD1d antigen binding groove, and in certain embodiments, an immunogen. The administration of compositions of the present invention affects the activity of CD1d-restricted NKT cells, and in particular, allows for multiple administrations without causing CD1d-restricted NKT cell anergy.

Described herein are combination methods, compositions and therapies for treating ophthalmic conditions or diseases arising from, associated with or leading to the overproduction of waste products in the visual cycle. Agents included within these combinations are 13-cis-retinyl derivatives; other agents included within these combinations are selected from vitamins, antioxidants, minerals, inducers of nitric oxide production, anti-inflammatory agents, and negatively-charged phospholipids. Such combination methods may be used as single or multiple administration therapies, or in combination with other agents or therapies.

The invention provides for the use of an accordion pill comprising levodopa for the treatment of symptoms of Parkinson's disease in a subject in need thereof over a 24 hour period, to be administered to the subject in a twice daily administration regimen, with an interval of about 8 to about 10 hours between the first dose and the second dose, and with an interval of about 14 to about 16 hours between the second dose and the first dose of the following day. The twice daily administration regimen provides a stable blood plasma level of levodopa in the subject after multiple administrations and is effective in treating the symptoms of Parkinson's disease over a 24 hour period.

The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH═CH—COO—(CH₂)n—NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group.

The pharmaceutical composition of the present invention is an intra-articular formulation that exerts rapid analgesic effects after administration, and shows extremely long durable effects for a human joint disease with only a single administration rather than multiple administrations of a conventional way.

The invention provides docetaxel polymer nano-micelle injection, and a preparation method and application thereof in preparation of tumor drugs; the docetaxel polymer nano-micelle injection comprises, by weight, 1 part of docetaxel and 10-100 parts of a nano-micelle polymer; the docetaxel nano-micelles are uniform in particle size and have 20-200 nm in average particle size. The docetaxel polymer nano-micelle injection can provide greatly improved water-solubility of docetaxel and has greatly improved stability, the cycle time of docetaxel in blood is extended, and toxic and side effects of commercially available preparations are decreased; docetaxel is passively targeted to a tumor part through EPR (enhanced permeability and retention) effect, anti-tumor effect of docetaxel is thereby improved, and the case that polymer nano-micelle preparations using PEG (polyethylene glycol) as a shell layer are not applicable (such as to the treatment of a patient having PEG antibodies or a patient having PEG antibodies generated in multiple administration) can be avoided.

The invention discloses a moldavica dragonhead total flavone sustained release tablet and a preparation method thereof. The moldavica dragonhead total flavone sustained release tablet is prepared by mixing, granulating and tabletting moldavica dragonhead total flavone, a framework material, filler, a caking agent and a lubricating agent. Compared with the prior art, the moldavica dragonhead total flavone sustained release tablet prepared by the method disclosed by the invention has the advantages of short development period, simple and easy production process, suitability for bulk production, favorable medicine release performance, favorable safety performance, simpler prescription, low research and development cost, convenience for taking, easy control for quality and the like. In addition, after the medicine is administrated, the slow release at non constant-speed can be realized, the blood-medicine concentration is more stable, the peak valley fluctuation is smaller and the toxic or side effects due to multiple administrations with the result that the blood-medicine concentration exceeds the treatment range can be avoided. Meanwhile, the moldavica dragonhead total flavone sustained release tablet can be maintained in the effective concentration range for a longer time so as to maintain the curative effect and improve the safety, the effectiveness and the adaptability of the medicine; and the medicine administration frequency each day is reduced to 1-2 times from 3-4 times, thus the moldavica dragonhead total flavone sustained release tablet is greatly convenient for patients and particularly patients required to administrate the medicine for a long term.

The invention relates to an isosorbide mononitrate micro-porous osmotic pump tablet and a preparation method thereof. The preparation can release isosorbide mononitrate at a constant drug release rate. The isosorbide mononitrate micro-porous osmotic pump tablet is mainly composed of a tablet core, a semipermeable coating film and drug release pores, wherein the tablet core consists of isosorbide mononitrate, an osmotic pressure active substance, filler and other pharmaceutical auxiliary materials; and the semipermeable coating film consists of cellulose acetate, a plasticizer and a pore former. The osmotic pressure between the outside and inside of the semipermeable film is used as the driving force and the osmotic pump tablet releases the drug at a zero order release rate, thus the tablet has the characteristics that the blood concentration is stable, the in-vivo drug action time is proper, the side effects are little and the drug resistance is hardly caused after multiple administration.

The invention relates to an injectable sustained release implant comprising degarelix acetate and a preparation method of the injectable sustained release implant. The implant is a liquid preparationprepared by dissolving degarelix acetate and a biodegradable high-molecular polymer into an appropriate organic solvent. The liquid preparation is injected into the human body through local subcutaneous or muscular injection, the solvent is rapidly dispersed into the surrounding tissue water, the polymer is not soluble in water, is solidified on the administration part, wraps the medicine to forma semi-solid or solid medicine storage reservoir, the medicine is slowly released along with the degradation of the polymer, so that the effect of long-acting controlled release is achieved. The implant has the advantages that the troublesome of multiple administration for a patient is reduced, the untoward effect of the medicine is reduced and the compliance is improved.

A dry powder norovirus vaccine is provided, which comprises at least two norovirus antigens representing different genogroups. The vaccine may be produced by formulation with a mixture of different antigens or combination of monovalent powders with each containing one antigen. The formulated vaccine is suitable for mucosal administration and soluble in aqueous solutions for parenteral administration. A method of immunization is also provided, which comprises at least one administration of the vaccine via mucosal and/or parental route. The immunization may have multiple administrations of the vaccine, i.e., one or more immunizations via a mucosal route followed by one or more immunizations via a parenteral route or vice versa, to maximize both mucosal and systemic immune responses and protection against norovirus infections.

The invention discloses a method for evaluating the bioavailability in combined application of fuke qianjin tablets and antibiotics. According to the method, the concentration of a drug to be detected in a blood plasma sample is detected, the pharmacokinetic parameters are calculated by using an ADAPT 5.1 software inverse Gaussian model, and each group of the parameters are subjected to statistical analysis with SPSS software so as to complete the evaluation, wherein the blood plasma sample is obtained after the single administration of antibiotic drugs or the combined administration of fuke qianjin tablets and antibiotics, the concentration of the drug to be detected is the concentration of the antibiotic drug, and the method for detecting the concentration of the drug to be detected in the blood plasma sample is a HPLC-ECD method or HPLC-ESI-MS method. According to the present invention, the pharmacokinetic evaluation method for the multiple administration of fuke qianjin tablets and azithromycin in chronic pelvic inflammatory disease rats is established, and the reliable method for evaluating the rationality of the combined administration of fuke qianjin tablets and azithromycin is achieved; and with the evaluation method, the pharmacokinetic rule of fuke qianjin tablets and azithromycin in chronic pelvic inflammatory disease rats can be successfully obtained, the scientific basis can be provided for the reasonable clinical application of fuke qianjin tablets and azithromycin, and the reference can be provided for the subsequent related research.

The invention relates to the field of medicines, and in particular relates to polypeptide which can inhibit MYC carcinogenic protein and treat tumor. The sequence of the polypeptide is as shown in SEQ ID NO.1. The polypeptide has the application of tumor treatment. The application includes tumor treatment in multiple administration modes, including subcutaneous or intramuscular injection, intravenous injection or intravenous drip, and the like. The polypeptide has the beneficial effects that in-vitro proliferation activity of multiple tumor cells can be inhibited, MYC protein expression in tumor cells can be promoted, telomerase activity of a tumor cell can be inhibited, growth of tumor inside tumor model naked mice can be inhibited, and the survival rate of tumor-bearing mice can be increased. An effect of treating tumor can be achieved.

The present invention provides an immunogen composition and methods for using the same for the development of immunity. In one method, the immunogen composition is administered to prepare a person for a later booster administration. This immunogen composition includes an antigen and a polyoxyalkylene block copolymer. In another method the booster administration is given to a person previously prepared for the booster through prior administration of the immunogen composition. Another method includes multiple administrations, with a later administration boosting the immune response from a prior administration.

The invention discloses a disposable oral administration device and an administration method, and belongs to the technical field of medical instruments. The oral administration device comprises a three-way connecting tube, an oral administration end and a first extension tube. A first connecting port and a second connecting port of the three-way connecting tube are separately connected with a first injector and a second injector. One end of the first extension tube is fixedly connected with the oral administration end to form a whole, and the other end of the first extension tube is detachablyconnected with a third connecting port of the three-way connecting tube. The oral administration end is designed as a cylindrical housing, the first extension tube communicates with the inside of thecylindrical housing, multiple administration holes are evenly distributed on both end surfaces of the cylindrical housing, so that the comfort of use of the oral administration device is improved, and the oral administration device is conveniently washed to reduce residues of radioactive drugs, and can be quickly replaced to avoid radioactive contamination.

The invention relates to the field of medicines, in particular relates to polypeptide which can inhibit mTOR and prevent and treat diabetes. The sequence of the polypeptide is EIQATWYEKLHEW. The application of the polypeptide in preventing or treating the diabetes can be realized by multiple administration methods including subcutaneous injection or intramuscular injection, intravenous injection or intravenous drip, oral administration such as pills or capsules, nasal sprays and the like. The polypeptide for inhibiting mTOR and application thereof have the beneficial effects that the mTOR can be inhibited in a targeted manner, the physiological and pathological effects generated by an mTOR receptor can be inhibited, and the effects of preventing and treating the diabetes can be achieved.

A drug delivery formulation for treating a mental illness or a central nervous system disorder is disclosed. The drug delivery formulation includes a microcapsule containing a biodegradable polymer and a drug and a crosslinked hydrogel and a method for preparing the same. The drug delivery formulation can slowly release a drug at a constant rate without a burst of drug release in the early stage of drug administration to maintain a constant blood drug level over a long period of time and thus enjoys the advantage of preventing excessive initial release of drug, thereby obtaining a desirable sustained release profile by single administration without necessity for multiple administrations divided at regular time intervals.